– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...

The Society of Interventional Radiology (SIR) announced that the CAPTAIN randomized clinical trial found that men with ...

Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a ...

A Yale-led study examines the potential environmental benefits of more carefully selecting patients for prostate biopsy in a way that can also spare low-yield and potentially harmful procedures. Yale ...

Mar 27, 2026, 7:45 AM ETProfound Medical Corp. (PROF), PRN:CA The TULSA Procedure, performed using the TULSA-PRO ® system, represents a major advancement in prostate care, and is used by physicians to ...